COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv

30,884 Articles (22,568 medRxiv, 8,316 bioRxiv)

Most recent first Previous |  Page 993: Articles 9921-9930  | Next

Predicting the course of Covid-19 and other epidemic and endemic disease
Cascon, A., Shadwick, W. F.
10.1101/2021.12.26.21268419 — Posted: 2021-12-29
A novel assessment method for COVID-19 humoral immunity duration using serial measurements in naturally-infected and vaccinated subjects.
de Boer, J., Saade, U., Granjon, E., Trouillet-Assant, S., Saade, C., Pottel, H., Zrein, M.
10.1101/2021.12.28.21268183 — Posted: 2021-12-29
Emergence in Southern France of a new SARS-CoV-2 variant of probably Cameroonian origin harbouring both substitutions N501Y and E484K in the spike protein
Colson, P., Delerce, J., Burel, E., Dahan, J., Jouffret, A., Fenollar, F., Yahi, N., Fantini, J., LA SCOLA, B., Raoult, D.
10.1101/2021.12.24.21268174 — Posted: 2021-12-29 Discussion: Onsite
COVID-19 in children in NSW, Australia, during the 2021 Delta outbreak: Severity and Disease spectrum
Williams, P., Koirala, A., Saravanos, G., Lopez, L., Glover, C., Sharma, K., Williams, T., Carey, E., Shaw, N., Dickins, E., Sitaram, N., Ging, J., Bray, P., Crawford, N., McMullan, B., Macartney, K., Wood, N., Fulton, B., Lau, C., Britton, P. N.
10.1101/2021.12.27.21268348 — Posted: 2021-12-29 Discussion: Onsite
Characteristics and outcomes of cases of children and adolescents with pediatric inflammatory multisystem syndrome in a tertiary care centre in Mexico City.
Gil Guevara, R., Marroquin Yanez, M. d. L., Jimenez-Juarez, R. N., Olivar Lopez, V., Lopez, A. C., Sienra Monge, J. J. L., Erdmenger Orellana, J., Jamaica Balderas, L. M. d. C., Martinez Herrera, S. A., Dominguez-Barrera, C., Marquez Gonzalez, H., Klunder-Klunder, M., Nieto-Zermeno, J., Villa Guillen, M., Garcia, N. G., Castilla Peon, M. F.
10.1101/2021.12.23.21268188 — Posted: 2021-12-29
Sociodemographic factors and self-restraint from social behaviors during the COVID-19 pandemic in Japan: a cross-sectional study
MORI, T., Nagata, T., Ikegami, K., Hino, A., Tateishi, S., Tsuji, M., Matsuda, S., Fujino, Y., Mori, K.
10.1101/2021.12.27.21268446 — Posted: 2021-12-29
Divergent SARS CoV-2 Omicron-specific T- and B-cell responses in COVID-19 vaccine recipients
GeurtsvanKessel, C. H., Geers, D., Schmitz, K. S., Mykytyn, A. Z., Lamers, M. M., Bogers, S., Gommers, L., Sablerolles, R. S. G., Nieuwkoop, N. N., Rijsbergen, L. C., van Dijk, L. L. A., de Wilde, J., Alblas, K., Breugem, T. I., Rijnders, B. J. A., de Jager, H., Weiskopf, D., van der Kuy, P. H. M., Sette, A., Koopmans, M. P. G., Grifoni, A., Haagmans, B. L., de Vries, R. D.
10.1101/2021.12.27.21268416 — Posted: 2021-12-29
Immunogenicity of heterologous BNT162b2 booster in fully vaccinated individuals with CoronaVac against SARS-CoV-2 variants Delta and Omicron: the Dominican Republic Experience
Perez-Then, E., Lucas, C., Monteiro, V. S., Miric, M., Brache, V., Cochon, L., Vogels, C. B. F., De la Cruz, E., Jorge, A., De los Santos, M., Leon, P., Breban, M. I., Billig, K., Yildirim, I., Pearson, C., Downing, R., Gagnon, E., Muyombwe, A., Razeq, J., Campbell, M., Ko, A., Omer, S. B., Grubaugh, N. D., Vermund, S. H., Iwasaki, A.
10.1101/2021.12.27.21268459 — Posted: 2021-12-29
Safety and immunogenicity of BNT162b2 mRNA COVID-19 vaccine in Japanese patients after allogeneic stem cell transplantation.
Watanabe, M., Yakushijin, K., Funakoshi, Y., Ohji, G., Sakai, H., Hojo, W., Saeki, M., Hirakawa, Y., Matsumoto, S., Sakai, R., Nagao, S., Kitao, A., Miyata, Y., Koyama, T., Saito, Y., Kawamoto, S., Ito, M., Murayama, T., Matsuoka, H., Minami, H.
10.1101/2021.12.28.21268477 — Posted: 2021-12-29
Capturing a crucial 'disorder-to-order transition' at the heart of the coronavirus molecular pathology - triggered by highly persistent, interchangeable salt-bridges
Roy, S., Ghosh, P., Bandyapadhyay, A., Basu, S.
10.1101/2021.12.29.474439 — Posted: 2021-12-29 Discussion: Onsite

RSS  Collection RSS | JSON

The feeds linked above output metadata for the 100 most recent papers in the collection.To access the metadata for the entire collection in JSON or XML, visit the collection API.

Subject Areas
* The Clinical Trials and Epidemiology subject categories are now closed to new submissions following the completion of bioRxiv's clinical research pilot project and launch of the dedicated health sciences server medRxiv (submit.medrxiv.org). New papers that report results of Clinical Trials must now be submitted to medRxiv. Most new Epidemiology papers also should be submitted to medRxiv, but if a paper contains no health-related information, authors may choose to submit it to another bioRxiv subject category (e.g., Genetics or Microbiology).